Eli Lilly to Acquire Autoimmune Drugmaker Merida Biosciences for Up to $2.9 Billion
Eli Lilly has agreed to buy Merida Biosciences in an all-cash deal worth up to $2.9 billion to accelerate its pipeline of treatments for serious autoimmune and allergic conditions. The acquisition strengthens the pharmaceutical company's position in the competitive immunology sector.